ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

CRBU vs INKT // PIOTROSKI F-SCORE QUALITY

Caribou Biosciences Inc. (NASDAQ) VS. MiNK Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: CRBU 1 — INKT 2
▲ PIOTROSKI F-SCORE QUALITY LEADER: CRBU
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CRBU VS. INKT) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC CRBU INKT SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — -10.68% — TIE /fcf-yield <GO>
Operating Margin -60.00% — — TIE /operating-margins <GO>
Net Profit Margin -60.00% — — TIE /net-margins <GO>
Revenue Growth (YoY) 11.70% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality ACTIVE 4/9 2/9 +2.00 CRBU /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 27.5 46.1 -18.63 INKT /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $47.7M $55.5M -$7.8M INKT /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR CRBU REV INKT REV CRBU GROSS % INKT GROSS % CRBU FCF INKT FCF
FY 2025 $11.2M $0 — — -$112.4M -$5.9M
FY 2024 $10.0M $0 — — -$143.1M -$9.6M
FY 2023 $34.5M $0 — — -$93.3M -$15.8M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CRBU // BETA —
INKT // BETA —